These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19298393)

  • 1. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.
    Radovits T; Bömicke T; Kökény G; Arif R; Loganathan S; Kécsán K; Korkmaz S; Barnucz E; Sandner P; Karck M; Szabó G
    Br J Pharmacol; 2009 Mar; 156(6):909-19. PubMed ID: 19298393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil.
    Radovits T; Arif R; Bömicke T; Korkmaz S; Barnucz E; Karck M; Merkely B; Szabó G
    Eur J Pharmacol; 2013 Jun; 710(1-3):110-9. PubMed ID: 23623933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta.
    Korkmaz S; Radovits T; Barnucz E; Neugebauer P; Arif R; Hirschberg K; Loganathan S; Seidel B; Karck M; Szabó G
    Eur J Pharmacol; 2009 Aug; 615(1-3):155-62. PubMed ID: 19482016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
    Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of vardenafil into storage solution protects the endothelium in a hypoxia-reoxygenation model.
    Veres G; Hegedűs P; Barnucz E; Zöller R; Radovits T; Korkmaz S; Kolonics F; Weymann A; Karck M; Szabó G
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):242-8. PubMed ID: 23751217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings.
    Fukuhara S; Tsujimura A; Okuda H; Yamamoto K; Takao T; Miyagawa Y; Nonomura N; Okuyama A
    J Sex Med; 2011 Apr; 8(4):1061-71. PubMed ID: 21269399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model.
    Loganathan S; Radovits T; Korkmaz S; Hirschberg K; Barnucz E; Weymann A; Bömicke T; Arif R; Karck M; Szabó G
    Thorac Cardiovasc Surg; 2012 Jun; 60(4):247-54. PubMed ID: 22252326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass.
    Szabó G; Radovits T; Veres G; Krieger N; Loganathan S; Sandner P; Karck M
    Eur J Cardiothorac Surg; 2009 Oct; 36(4):657-64. PubMed ID: 19523842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Phosphodiesterase-5 by Vardenafil Improves Vascular Graft Function.
    Veres G; Hagenhoff M; Schmidt H; Radovits T; Loganathan S; Bai Y; Korkmaz-Icöz S; Brlecic P; Sayour AA; Karck M; Szabó G
    Eur J Vasc Endovasc Surg; 2018 Aug; 56(2):256-263. PubMed ID: 29724533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3',5'-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells.
    Komori K; Tsujimura A; Takao T; Matsuoka Y; Miyagawa Y; Takada S; Nonomura N; Okuyama A
    J Sex Med; 2008 Jul; 5(7):1623-35. PubMed ID: 18331270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.
    Morelli A; Filippi S; Sandner P; Fibbi B; Chavalmane AK; Silvestrini E; Sarchielli E; Vignozzi L; Gacci M; Carini M; Vannelli GB; Maggi M
    J Sex Med; 2009 Jun; 6(6):1594-1608. PubMed ID: 19473460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
    Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
    J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of vascular reactivity in normal, hypertensive and diabetic rat aortae by a non-antioxidant flavonoid.
    Ajay M; Achike FI; Mustafa MR
    Pharmacol Res; 2007 May; 55(5):385-91. PubMed ID: 17317209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model.
    Turgut NH; Temiz TK; Bagcivan I; Turgut B; Gulturk S; Karadas B
    Eur J Pharmacol; 2008 Jul; 589(1-3):180-7. PubMed ID: 18538317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus.
    Schäfer A; Fraccarollo D; Pförtsch S; Flierl U; Vogt C; Pfrang J; Kobsar A; Renné T; Eigenthaler M; Ertl G; Bauersachs J
    Br J Pharmacol; 2008 Mar; 153(5):886-93. PubMed ID: 17891166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
    Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
    Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo effects of vardenafil (a PDE-5 Inhibitor) on corpus cavernosal smooth muscle relaxation in diabetic rabbits.
    Lau DH; Mumtaz FH; Mikhailidis DP; Thompson CS
    Urol Int; 2009; 82(1):101-7. PubMed ID: 19172107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
    Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
    Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.